WO2026133193 - A METHOD TO GENERATE IMMUNO-FREE AND STRESS-RESISTANT DONOR CELLS
National phase entry is expected:
Publication Number
WO/2026/133193
Publication Date
25.06.2026
International Application No.
PCT/IB2025/063055
International Filing Date
17.12.2025
Title **
[English]
A METHOD TO GENERATE IMMUNO-FREE AND STRESS-RESISTANT DONOR CELLS
[French]
PROCÉDÉ POUR GÉNÉRER DES CELLULES DONNEUSES SANS RÉACTIVITÉ IMMUNOLOGIQUE ET RÉSISTANTES AU STRESS
Applicants **
MAHRAT, Reem
Inventors
MAHRAT, Reem
Priority Data
18/985,962
18.12.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
ILPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Natural Person
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2458 | |
| EPO | Filing, Examination, Granting | 13198 | |
| Japan | Filing, Examination, Granting | 2589 | |
| South Korea | Filing, Examination, Granting | 2994 | |
| USA | Filing, Examination, Granting | 9140 |
Total:
30,379
Contact Us
Abstract[English]
A method for generating immuno-free and stress-resistant donor cells comprising editing PRDM1 and FOXP3 genes in T-cells and B-cells with CRISPR-Cas9 and modulating immune responses to reduce inflammation and prevent autoimmunity. Particularly, the present invention discloses a method for treating Type 1 Diabetes, comprising genetically modifying pancreatic beta cells with CRISPR-Cas9, and altering HLA expression, and upregulating immune checkpoint molecules such as PD-L1 to obtain immune-tolerant and stress-resistant pancreatic beta cells.[French]
Procédé de génération de cellules donneuses sans réactivité immunologique et résistantes au stress, comportant l'édition des gènes PRDM1 et FOXP3 dans les lymphocytes T et les lymphocytes B à l'aide de CRISPR-Cas9, ainsi que la modulation des réponses immunitaires afin de réduire l'inflammation et de prévenir l'auto-immunité. Plus particulièrement, la présente invention concerne une méthode de traitement du diabète de type 1, comportant la modification génétique de cellules bêta pancréatiques à l'aide de CRISPR-Cas9, la modification de l'expression des molécules HLA et la régulation vers le haut de molécules de points de contrôle immunitaires telles que le PD-L1, afin d'obtenir des cellules bêta pancréatiques immunotolérantes et résistantes au stress.